|
Novartis International AG |
|
|
Basel, CH-4002 Switzerland
phone:+41 61 324 11 11
fax:+1 +41 61 324 80 01
|
|
| Symbol |
NVS |
| Exchange |
NYSE |
| Founded |
1996 |
| Employees |
72877 |
|
|
| www.novartis.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Throughout the years, Novartis and its predecessor companies have discovered and developed many innovative products for patients and consumers worldwide. |
|
| Management |
| Daniel Vasella, M.D., Chairman and CEO; Ulrich Lehner, Ph.D., Vice Chairman and Lead Director; Hans-Joerg Rudloff, Vice Chairman; William Brody, M.D; Ph.D.Srikant Datar, Ph.D. |
| |
|
|
|
|
|
|
| |
|
|
|
|
| Keywords |
| diovan, hypertension, eucreas, galvus, lescol |
|
|
|
|
|
|
| Description |
|
Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz, two companies with a rich and diverse corporate history. Throughout the years, Novartis and its predecessor companies have dis...
view more
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members